Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

被引：135

作者：

Drexler, I

Staib, C

Sutter, G ^{[1
]}

机构：

[1] Paul Ehrlich Inst, Dept Virol, D-63225 Langen, Germany

[2] GSF Munich, Inst Mol Virol, Munich, Germany

[3] Tech Univ Munich, Inst Virol, D-8000 Munich, Germany

来源：

CURRENT OPINION IN BIOTECHNOLOGY | 2004年 / 15卷 / 06期

关键词：

D O I：

10.1016/j.copbio.2004.09.001

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Safety-tested modified vaccinia virus Ankara (MVA) has been established as a potent vector system for the development of candidate recombinant vaccines. The versatility of the vector system was recently demonstrated by the rapid production of experimental MVA vaccines for immunization against severe acute respiratory syndrome associated coronavirus. Promising results were also obtained in the delivery of Epstein-Barr virus or human cytomegalovirus antigens and from the clinical testing of MVA vectors for vaccination against immunodeficiency virus, papilloma virus, Plasmodium falciparum or melanoma. Moreover, MVA is considered to be a prime candidate vaccine for safer protection against orthopoxvirus infections. Thus, vector development to challenge dilemmas in vaccinology or immunization against poxvirus biothreat seems possible, yet the right choice should be made for a most beneficial use.

引用

页码：506 / 512

页数：7

共 57 条

[1] Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication [J].

Allen, TM ;

Mortara, L ;

Mothé, BR ;

Liebl, M ;

Jing, PC ;

Calore, B ;

Piekarczyk, M ;

Ruddersdorf, R ;

O'Connor, DH ;

Wang, X ;

Wang, CX ;

Allison, DB ;

Altman, JD ;

Sette, A ;

Desrosiers, RC ;

Sutter, G ;

Watkins, DI .

JOURNAL OF VIROLOGY, 2002, 76 (08) :4108-4112

[2] Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].

Amara, RR ;

Villinger, F ;

Altman, JD ;

Lydy, SL ;

O'Neil, SP ;

Staprans, SI ;

Montefiori, DC ;

Xu, Y ;

Herndon, JG ;

Wyatt, LS ;

Candido, MA ;

Kozyr, NL ;

Earl, PL ;

Smith, JM ;

Ma, HL ;

Grimm, BD ;

Hulsey, ML ;

Miller, J ;

McClure, HM ;

McNicholl, JM ;

Moss, B ;

Robinson, HL .

SCIENCE, 2001, 292 (5514) :69-74

[3] Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines [J].

Amara, RR ;

Villinger, F ;

Staprans, SI ;

Altman, JD ;

Montefiori, DC ;

Kozyr, NL ;

Xu, Y ;

Wyatt, LS ;

Earl, PL ;

Herndon, JG ;

McClure, HM ;

Moss, B ;

Robinson, HL .

JOURNAL OF VIROLOGY, 2002, 76 (15) :7625-7631

[4] Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus [J].

Anderson, RJ ;

Hannan, CM ;

Gilbert, SC ;

Laidlaw, SM ;

Sheu, EG ;

Korten, S ;

Sinden, R ;

Butcher, GA ;

Skinner, MA ;

Hill, AVS .

JOURNAL OF IMMUNOLOGY, 2004, 172 (05) :3094-3100

[5] Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses [J].

Belyakov, IM ;

Earl, P ;

Dzutsev, A ;

Kuznetsov, VA ;

Lemon, M ;

Wyatt, LS ;

Snyder, JT ;

Ahlers, JD ;

Franchini, G ;

Moss, B ;

Berzofsky, JA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (16) :9458-9463

[6] Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates [J].

Bertley, FMN ;

Kozlowski, PA ;

Wang, SW ;

Chappelle, J ;

Patel, J ;

Sonuyi, O ;

Mazzara, G ;

Montefiori, D ;

Carville, A ;

Mansfield, KG ;

Aldovini, A .

JOURNAL OF IMMUNOLOGY, 2004, 172 (06) :3745-3757

[7] Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice [J].

Bisht, H ;

Roberts, A ;

Vogel, L ;

Bukreyev, A ;

Collins, PL ;

Murphy, BR ;

Subbarao, K ;

Moss, B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (17) :6641-6646

[8] Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals [J].

Cosma, A ;

Nagaraj, R ;

Bühler, S ;

Hinkula, J ;

Busch, DH ;

Sutter, G ;

Goebel, FD ;

Erfle, V .

VACCINE, 2003, 22 (01) :21-29

[9] Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus [J].

Cosma, A ;

Bühler, S ;

Nagaraj, R ;

Staib, C ;

Hammarin, AL ;

Wahren, B ;

Goebel, FD ;

Erfle, V ;

Sutter, G .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (02) :406-410

[10] Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination:: A phase I trial in metastatic melanoma [J].

Di Nicola, M ;

Carlo-Stella, C ;

Mortarini, R ;

Baldassari, P ;

Guidetti, A ;

Gallino, GF ;

Del Vecchio, M ;

Ravagnani, F ;

Magni, M ;

Chaplin, P ;

Cascinelli, N ;

Parmiani, G ;

Gianni, AM ;

Anichini, A .

CLINICAL CANCER RESEARCH, 2004, 10 (16) :5381-5390

← 1 2 3 4 5 6 →